Economic Burden Of Uterine Fibroids: Cost Of Treatment And Lost Productivity
Published on: May 8, 2025
Economic Burden of Uterine Fibroids Cost of Treatment and Lost Productivity
Article author photo

Katie Swanson

Master of Global Health (Graduate July 2025)

Article reviewer photo

Maya Khimji

BA Global Health and Social Medicine, King’s College London

Navigating uterine fibroids can be stressful and overwhelming, and you may be considering what the economic burden may entail. From NHS to private care, to lost productivity at work, this article can provide an overview of the economic realities associated with uterine fibroids. Understanding the costs in greater detail can allow for adequate planning and, in turn, reduce stress and the overwhelming nature of managing the effects. 

In the UK, the economic burden of uterine fibroids is felt in multiple different dimensions, both on an individual and a societal level. Treatment can be sought from the NHS, which can put a strain on the public health services. However, there are often long waiting lists, and resultantly many patients seek private care, which can be costly. Finally, there are often significant indirect costs through work-related impacts. 

The common costs associated with Uterine Fibroids are detailed below: 

  • NHS or Private Care: While fibroid treatment is provided for free on the NHS, individuals assigned female at birth (AFAB) report long waiting times, which can often lead to patients seeking private care. Private care costs will vary depending on the severity of your condition, however, it can cost upwards of £7,000 
  • OOP: Furthermore, even when care is sought through the NHS, there can be a number of costs incurred, including but not limited to: transport, childcare, and unpaid leave 
  • Lost Productivity: Many of those suffering from fibroids report that the symptoms can lead to frequent absences from work, reduced job productivity, and, in extreme cases, patients are forced to leave employment to manage their symptoms. This results in a significant loss of income for the patients, and can lead to pressure on employers
  • Wider Economic Impact: The condition, when not treated effectively, can contribute to a significant loss of working days each year, which can lead to significant economic loss throughout the UK

Fibroids can have a significant burden on your life, directly and indirectly and in terms of economic impact, but also physically and socially. Whilst experts demand more research must be done into these burdens within the UK and Europe, you can find out what we do know about the economic burden of fibroids, and the condition more generally, below. 

Fibroids: an overview 

Fibroids, often known as leiomyomas, are non-cancerous tumours that form on or around the uterus of AFAB individuals.2 They are the most common benign tumour in individuals AFAB, whilst they are found in 50% of persons AFAB of reproductive age, 1 in 2 persons AFAB will not know they have fibroids as they will be asymptomatic.1,2 However, for those who do experience symptoms, it is important to understand how they will affect you, the burden of the condition, and what you can do about it. 

Symptoms are experienced by around 1 in 3 of those who have fibroids.2 The most commonly reported symptoms are: 

  • Heavy menstrual bleeding3
  • Pelvic pain1
  • Tummy or abdominal pain2
  • Frequent need to urinate3
  • Pain during sexual intercourse2

In very severe cases, fibroids can cause fertility issues; however, this is rare.1

Prevalence of fibroids 

In the UK, the overall incidence of fibroids is 5.8 per 1,000 women-years.4 This means that out of every 1,000 AFAB individuals in the UK, around 6 will be diagnosed with uterine fibroids each year. However, the spread of this is not entirely equal. The proportion is significantly higher for black persons AFAB, at 59%, compared with white persons AFAB, at 43%.5 Resultantly, once AFAB individuals reach the age of 50, the cumulative incidence of fibroids for black women is over 80%, whereas 70% for white persons AFAB.5 This disparity should be further considered within research and policy. 

Direct costs and treatment

Whilst many who have fibroids will not need to be treated, as they will not experience any symptoms, around 1 in 3 persons AFAB will need to seek treatment. Within the UK, fibroid treatment is available through the NHS free of charge.2 Whilst the treatment itself is free of charge, patients may suffer the economic burden of travel to appointments, time off work, and childcare. 

There are many treatment options available. You should discuss what will be most appropriate for you with your healthcare provider, however, the most common procedures include: 

  • Medication to Relieve Pain Symptoms: Typically, the first step involves the least invasive treatment, which involves prescribing pain relief medicine to try and ease the symptoms.2 Prescriptions will vary, but may be non-steroidal anti-inflammatory drugs (NSAIDs), for example, ibuprofen 
  • Methods to Reduce Heavy Period Symptoms: Your care provider may recommend methods to reduce the severity of your bleeding and period. These may include the contraceptive pill, oral progestogen, or tranexamic acid 
  • Medicine to Shrink Fibroids: If the above is unsuccessful in relieving your symptoms, your healthcare provider may prescribe treatment to reduce the size of the fibroids. This may include Gonadotropin-releasing hormone analogues (GnRHas) and Ulipristal 

In severe cases, where symptoms are extreme or medication is unsuccessful in relieving symptoms, you may consider surgery to remove the fibroids. You will be referred to a specialist who will discuss the available options, however, the most common surgeries include hysterectomy, myomectomy, and hysteroscopic resection of fibroids. There are also a number of non-surgical procedures that can treat fibroids. 

Often, seeking surgical and non-surgical treatment of fibroids on the NHS can unfortunately have lengthy waiting periods. As a result, many choose to seek private care for these procedures, which can be extremely costly. The initial consultation with a private specialist can average between £200-£500. A privately performed myomectomy, which involves the removal of the fibroids, may cost between £5,000 to £12,500.6 The private cost of fibroid care will have a significant economic burden on the patient. Many suggest more can be done by the NHS in order to reduce the number of patients who feel they have no other option due to the severity of their symptoms. 

Indirect costs 

While the physical cost of private treatment can have an economic burden on the patient, several indirect costs can take their toll.1 These extend beyond direct healthcare expenses. Indirect costs include, but are not limited to, decreased capacity to perform in the workplace, absenteeism, and general negative impact on daily life and functioning.7 Below is an insight into the commonly reported indirect economic burdens and how they impair patients' lives: 

Reduced job productivity

Those who experience severe symptoms of fibroids may suffer from pain, heavy bleeding, or fatigue during the working day, which can impact job productivity. Studies have proven that those suffering from fibroids have a higher activity impairment than their healthy coworkers.1 This can have a significant economic burden on both the country and in some cases limit the patients career progression and opportunities. 

Absenteeism

Similarly, symptoms and associated medical procedures can result in increased missed work days. These can add up, and whilst sick leave should be provided can often result in unpaid leave, which can have a severe economic impact on the patient.4

Quality of life

The symptoms of fibroids can take a toll on women’s overall well-being, quality of life, and mental health.1 The reduced quality of life can have detrimental impacts. Further, this can have a direct economic burden. Patients may incur additional costs, including support services or costly adjustments to daily life.8

The indirect costs of fibroids are estimated to have a significant contribution to the overall economic burden associated with the condition, and should always be considered. 

FAQs

Can I receive fibroid treatment on the NHS?

Yes, various high-quality and effective fibroid treatments are available on the NHS. However, wait times can be significant. You should be sure to discuss all available options with your health care professionals. 

If you have medical insurance or the means to seek private care, it may result in more timely treatment. 

Am I protected in the workplace for fibroid-related sick leave?

Yes, the standard sick leave policy applies. However, menstrual health remains poorly understood in many workplaces. You should communicate clearly with your manager and seek support if you feel uncomfortable or undersupported by your employer. 

What will happen if I do not seek treatment for my fibroid?

You do not have to be treated, especially if you are not experiencing symptoms. Often, fibroids will shrink after menopause without treatment. However, if they are causing you pain or discomfort, there are a plethora of treatments available to support you.

Summary 

Uterine fibroids, whilst benign, carry a significant economic burden for women. Treatment is available on the NHS free of charge, however, many feel pushed towards private care as a result of long waiting times, which can result in costs of £12,000. Even when care is sought on the NHS, additional travel, childcare, and unpaid leave can result in an economic impact. 

Beyond direct healthcare expenses, fibroids have devastating indirect costs, including lost productivity, absenteeism from symptoms, and an overall decrease in quality of life. Research suggests that the indirect costs of fibroids could be costing millions across the UK annually. 

More research and support surrounding the direct and indirect economic burden of fibroids is essential to alleviate suffering and care for victims throughout the UK.

References

  • Hasselrot K, Lindeberg M, Konings P, Kopp Kallner H. Investigating the loss of work productivity due to symptomatic leiomyoma. Hawkins SM, editor. PLOS ONE. 2018 Jun 11;13(6):e0197958.
  • NHS . Overview - Fibroids [Internet]. NHS. 2019. Available from: https://www.nhs.uk/conditions/fibroids/
  • iswanathan M, Hartmann K, McKoy N, Stuart G, Rankins N, Thieda P, et al. Management of uterine fibroids: an update of the evidence. PubMed. 2007 Jul 1;
  • Martín-Merino E, Wallander MA, Andersson S, Soriano-Gabarró M, Rodríguez LAG. The reporting and diagnosis of uterine fibroids in the UK: an observational study. BMC Women’s Health. 2016 Jul 25;16(1).
  • NICE CKS. (2023). Prevalence - Background Information - Fibroids - Nice CKS. [online] Available at: https://cks.nice.org.uk/topics/fibroids/background-information/prevalence/ [Accessed 25 Apr. 2025
  • awits. Fees: Fibroids Consultations, Treatment & Surgery | London Fibroids [Internet]. London-fibroids.com. 2014 [cited 2025 Apr 25]. Available from: https://www.london-fibroids.com/fees/
  • Danya Lakshmi Chandrakumar, Mehrnoosh Aref-Adib, Funlayo Odejinmi. Advancing women’s health: The imperative for public health screening of uterine fibroids for personalized care. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2024 Aug 1;299:266–71.
  • Soliman AM, Yang H, Du EX, Kelkar SS, Winkel C. The direct and indirect costs of uterine fibroid tumors: a systematic review of the literature between 2000 and 2013. American Journal of Obstetrics and Gynecology [Internet]. 2015 Aug 1 [cited 2021 Feb 11];213(2):141–60. Available from: https://pubmed.ncbi.nlm.nih.gov/25771213/

Share

Katie Swanson

Master of Global Health (Graduate July 2025)
MA (hons) Geography and Social Anthropology (2024)

arrow-right